Mirum Pharmaceuticals (MIRM) News Today → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free MIRM Stock Alerts $24.42 +0.25 (+1.03%) (As of 04/23/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineMirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Valueseekingalpha.com - April 22 at 5:39 PMKnights of Columbus Asset Advisors LLC Grows Stock Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)marketbeat.com - April 21 at 6:39 AMMirum Pharmaceuticals (NASDAQ:MIRM) Shares Gap Up to $24.01americanbankingnews.com - April 19 at 5:36 AMMirum Pharmaceuticals (NASDAQ:MIRM) Now Covered by Stifel Nicolausamericanbankingnews.com - April 19 at 1:58 AMStifel starts Mirum at buy, cites IBATi drug potentialmsn.com - April 18 at 1:43 PMStifel Initiates Coverage of Mirum Pharmaceuticals (MIRM) with Buy Recommendationmsn.com - April 17 at 9:44 PMStifel Nicolaus Initiates Coverage on Mirum Pharmaceuticals (NASDAQ:MIRM)marketbeat.com - April 17 at 3:51 PMBuy Rating Affirmed for Mirum Pharmaceuticals Amidst Strategic Positioning and Treatment Breakthroughsmarkets.businessinsider.com - April 17 at 6:43 AMMirum Pharmaceuticals (NASDAQ:MIRM) Reaches New 1-Year Low at $24.17americanbankingnews.com - April 17 at 5:16 AMBuy Rating Affirmed for Mirum Pharmaceuticals Amid Positive Clinical Trial Outlookmarkets.businessinsider.com - April 16 at 5:53 PMMirum Pharmaceuticals (NASDAQ:MIRM) Sets New 1-Year Low at $24.17marketbeat.com - April 15 at 10:57 AMMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)businesswire.com - April 10 at 9:30 PMMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Consensus Rating of "Buy" by Analystsmarketbeat.com - April 9 at 4:10 AMVanguard Group Inc. Acquires 98,685 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)marketbeat.com - April 9 at 4:08 AMMirum Pharmaceuticals (NASDAQ:MIRM) Stock Rating Reaffirmed by HC Wainwrightmarketbeat.com - April 2 at 12:13 PMMirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndromefinance.yahoo.com - April 2 at 9:42 AMMirum Pharmaceuticals' LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada's CADTH for Patients with Cholestatic Pruritus in Alagille Syndromebusinesswire.com - April 2 at 8:30 AMEric Bjerkholt Purchases 2,000 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stockinsidertrades.com - March 28 at 8:46 AMEric Bjerkholt Acquires 2,000 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stockmarketbeat.com - March 27 at 9:29 PMMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Sells $111,017.40 in Stockinsidertrades.com - March 26 at 4:44 AMMirum Pharmaceuticals Inc (MIRM) Insider Sells Sharesfinance.yahoo.com - March 26 at 4:07 AMMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich Sells 4,303 Sharesmarketbeat.com - March 25 at 9:31 PMLeerink Partnrs Equities Analysts Boost Earnings Estimates for Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)marketbeat.com - March 20 at 6:39 AMMirum Pharmaceuticals COO sells over $28k in company stockinvesting.com - March 20 at 5:21 AMLeerink Partnrs Analysts Reduce Earnings Estimates for Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)marketbeat.com - March 19 at 6:55 AMEric Bjerkholt Buys 2,000 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stockinsidertrades.com - March 19 at 5:38 AMCracking The Code: Understanding Analyst Reviews For Mirum Pharmaceuticalsmarkets.businessinsider.com - March 18 at 6:15 PMJMP Securities Boosts Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $72.00marketbeat.com - March 18 at 5:59 PMMirum Pharmaceuticals (NASDAQ:MIRM) Stock Price Down 3.9%marketbeat.com - March 15 at 3:34 PMMIRM Mar 2024 40.000 callca.finance.yahoo.com - March 15 at 10:56 AMBuy Rating Affirmed for Mirum Pharmaceuticals Following FDA Approval and Promising Pipeline Developmentsmarkets.businessinsider.com - March 15 at 10:56 AMMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Average Rating of "Buy" by Analystsmarketbeat.com - March 15 at 6:41 AMFDA Approves Mirum's Livmarli For Liver Disease In Kids As Young As 5 Years: Analyst Bullish On Label Expansion Strategymsn.com - March 14 at 5:34 PMMirum Pharmaceuticals Gets Additional FDA Approval for Livmarlimarketwatch.com - March 14 at 12:33 PMBuy Rating Affirmed for Mirum Pharmaceuticals Following FDA Approval and Positive Revenue Outlookmarkets.businessinsider.com - March 14 at 7:32 AM3 Best Stocks to Buy Now, 3/14/2024, According to Top Analystsmsn.com - March 14 at 7:32 AMMirum gains as FDA accepts label expansion of liver disease drugmsn.com - March 14 at 7:32 AMUS FDA approves expanded use of Mirum's liver disease drugreuters.com - March 13 at 8:14 PMMirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasisfinance.yahoo.com - March 13 at 8:14 PMMirum Pharmaceuticals' LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasisbusinesswire.com - March 13 at 6:00 PMPolar Capital Holdings Plc Increases Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)marketbeat.com - March 12 at 10:35 AMMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)businesswire.com - March 8 at 7:30 PMAdage Capital Partners GP L.L.C. Acquires New Shares in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)marketbeat.com - March 7 at 7:44 AMMirum Pharmaceuticals: Advancing On Several Key Frontsseekingalpha.com - March 5 at 5:29 AMArdsley Advisory Partners LP Takes Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)marketbeat.com - March 3 at 11:16 AMMirum Pharmaceuticals, Inc. (MIRM) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 1 at 6:57 PMCritical Insights From Mirum Pharmaceuticals Analyst Ratings: What You Need To Knowmarkets.businessinsider.com - February 29 at 2:56 PMHepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum's LIVMARLIstockhouse.com - February 29 at 9:55 AMAnalysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM) and Integra Lifesciences (IART)markets.businessinsider.com - February 29 at 9:55 AMHepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum’s LIVMARLIfinance.yahoo.com - February 29 at 9:55 AM Get Mirum Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIRM and its competitors with MarketBeat's FREE daily newsletter. Email Address Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better. Click here to find out that this 8,788% cryptocurrency is. MIRM Media Mentions By Week MIRM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MIRM News Sentiment▼0.360.45▲Average Medical News Sentiment MIRM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MIRM Articles This Week▼104▲MIRM Articles Average Week Get Mirum Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIRM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: AbCellera Biologics News Today MannKind News Today Gemini Therapeutics News Today Xencor News Today Collegium Pharmaceutical News Today Deciphera Pharmaceuticals News Today Prothena News Today Pieris Pharmaceuticals News Today Belite Bio News Today Ligand Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MIRM) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyHe Is Giving Away BitcoinCrypto Swap ProfitsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersHow to camouflage a factory of 53,000 workersStansberry ResearchDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mirum Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
